Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
NCT07364305Phase 2Recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, pembrolizumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Eastern Hepatobiliary Surgery Hospital. Started Jan 2025; status: recruiting.
02
Drugs
durvalumabpembrolizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07364305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364305.